Patients & Visitors

Acute Stroke Unit


Stroke Research

Research is important because it helps to improve healthcare by finding out which treatments work best.

The stroke team is committed to providing the best possible care for our patients and our team includes research nurses who organise the studies and work with patients who take part in these studies.

We are part of the West of England Clinical Research Network and are involved in several national and international trials.

The studies are looking into various aspects of the care and treatment of patients who have had a stroke or TIA (mini stroke), including improving recovery and preventing further strokes, as well as looking for possible genetic causes of stroke.

All the research undertaken is approved by the trust, and is deemed to be ethical and safe. Participation is entirely voluntary, and does not affect normal patient care.

If you would like to know more about our studies and how you can participate, please contact the Stroke Research Team on 01225 82 4120

Further information about clinical trials

A 5 minute video from the Medical Research Council Clinical Research Unit.

A pamphlet from the National Institute for Health Research.

Click here to view

A pamphlet from the National Institute for Health Research.

Click here to view

OK to ask aims to encourage more patients or carers to ask about research opportunities.

Click here to view

Research Studies

RESTART : Restart or stop antithrombotics trial in patients with intracranial haemorrhage

RESTORE: Randomized Efficacy and Safety Trial with Oral S 44819 after Recent ischemic cerebral Event
International, multi-centre, randomized, double-blind placebo controlled phase II study.
Main criteria for inclusion:
Patients, aged 18-80 years (both inclusive), with a recent (≤144 hours (or 6 days)) supratentorial cortical ischemic stroke, with no previous disability (i.e. neither physical nor pre-stroke cognitive impairment).

PLORAS: Predicting Language outcome and recovery after stroke

POINT: The purpose of this study is to determine the safety and effectiveness of the combination of low-dose aspirin and a medication called clopidogrel (also known by the brand name Plavix®) in reducing the risk of stroke, heart attacks and other complications in patients who have just had a TIA or minor ischemic stroke.

RIGHT-2: Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke Trial 2 - Assessment of safety and efficacy of transdermal glyceryl trinitrate, a nitric oxide donor, and of the feasibility of a multi-centred ambulance based stroke trial.

SIGNUM: Stroke Investigation Network-Understanding Mechanisms.

XILO-FIST: Xanthine oxidase inhibition for improvement of long-term outcomes following Ischaemic Stroke and Transient Ischaemic Attack.

INTERACT2: Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial. The INTERACT2 study found that patients who suffered an acute intracerebral haemorrhage and received fast blood pressure lowering treatment within 6 hrs were better off both physically and psychologically. This treatment regime has since been implemented here at the RUH.

SO2S: Stroke Oxygen Study: A multi-centre, prospective, randomised, open, blinded-endpoint study to assess whether routine oxygen treatment in the first 72 hours after a stroke improves long-term outcome: There is no evidence to support giving routine Oxygen to stroke patients. The study found that there was no difference in outcome between the 3 trial groups (O2 given at night for 3 nights, continuous O2 for 72 hours or no oxygen). Therefore we need to continue our normal practice of monitoring patients routinely and only give Oxygen if indicated according to patients' SaO2.

ENOS: The 'Efficacy of Nitric Oxide in Stroke' (ENOS) study is a controlled trial designed to test the safety and efficacy of transdermal glyceryl trinitrate (a nitric oxide donor) or control; and continuing or temporarily stopping prior anti-hypertensive medication. No difference in outcome was found in the GTN groups. Also, there was no evidence to support continuing pre-stroke blood pressure medication in patients in the acute phase of stroke. Of particular interest was that patients who did continue oral BP medication - despite having swallowing problems - had a higher incidence of pneumonia. Therefore, antihypertensive medication can be continued once the patient is stable and safe enteral access has been established.

IRIS – The Insulin Resistance Intervention after stroke trial – a randomised placebo-controlled trial of pioglitazone, compared with placebo, for prevention of stroke and myocardial infarction after ischemic stroke and transient ischemic attack.

In this multi-centre, double-blind trial, Patients were randomly assigned either pioglitazone or placebo. This trial involved patients without diabetes who had insulin resistance along with a recent history of ischemic stroke or TIA, the risk of stroke or myocardial infarction was lower among patients who received pioglitazone than among those who received placebo. Pioglitazone was also associated with a lower risk of diabetes but with higher risks of weight gain, edema, and fracture. (Funded by the National Institute of Neurological Disorders and Stroke)

This was a landmark study demonstrating that treatment of insulin resistance in stroke survivors reduces the subsequent risk of stroke and myocardial infarction.

back to top